Strengthening the occupational and social participation of multiple sclerosis patients - design of a multicenter, parallel-group randomized controlled trial (MSnetWork-study).
Ability to work
Germany
Health economic research
Health service research
Health-related quality of life (HRQoL)
Incapacity to work
Multiple sclerosis
Study protocol
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
09 Dec 2022
09 Dec 2022
Historique:
received:
02
08
2022
accepted:
28
10
2022
entrez:
9
12
2022
pubmed:
10
12
2022
medline:
15
12
2022
Statut:
epublish
Résumé
Multiple Sclerosis is an autoimmune inflammatory disease of the central nervous system that often leads to premature incapacity for work. Therefore, the MSnetWork project implements a new form of care and pursues the goal of maintaining or even improving the state of health of MS patients and having a positive influence on their ability to work as well as their participation in social life. A network of neurologists, occupational health and rehabilitation physicians, psychologists, and social insurance suppliers provide patients with targeted services that have not previously been part of standard care. According to the patient's needs treatment options will be identified and initiated. The MSnetWork study is designed as a multicenter randomized controlled trial, with two parallel groups (randomization at the patient level with 1:1 allocation ratio, planned N = 950, duration of study participation 24 months). After 12 months, the patients in the control group will also receive the interventions. The primary outcome is the number of sick leave days. Secondary outcomes are health-related quality of life, physical, affective and cognitive status, fatigue, costs of incapacity to work, treatment costs, out-of-pocket costs, self-efficacy, and patient satisfaction with therapy. Intervention effects are analyzed by a parallel-group comparison between the intervention and the control group. Furthermore, the long-term effects within the intervention group will be observed and a pre-post comparison of the control group, before and after receiving the intervention in MSnetWork, will be performed. Due to the multiple approaches to patient-centered, multidisciplinary MS care, MSnetWork can be considered a complex intervention. The study design and linkage of comprehensive, patient-specific primary and secondary data in an outpatient setting enable the evaluation of this complex intervention, both on a qualitative and quantitative level. The basic assumption is a positive effect on the prevention or reduction of incapacity for work as well as on the patients' quality of life. If the project proves to be a success, MSnetWork could be adapted for the treatment of other chronic diseases with an impact on the ability to work and quality of life. The trial MSnetWork has been retrospectively registered in the German Clinical Trials Register (DRKS) since 08.07.2022 with the ID DRKS00025451 .
Sections du résumé
BACKGROUND
BACKGROUND
Multiple Sclerosis is an autoimmune inflammatory disease of the central nervous system that often leads to premature incapacity for work. Therefore, the MSnetWork project implements a new form of care and pursues the goal of maintaining or even improving the state of health of MS patients and having a positive influence on their ability to work as well as their participation in social life. A network of neurologists, occupational health and rehabilitation physicians, psychologists, and social insurance suppliers provide patients with targeted services that have not previously been part of standard care. According to the patient's needs treatment options will be identified and initiated.
METHODS
METHODS
The MSnetWork study is designed as a multicenter randomized controlled trial, with two parallel groups (randomization at the patient level with 1:1 allocation ratio, planned N = 950, duration of study participation 24 months). After 12 months, the patients in the control group will also receive the interventions. The primary outcome is the number of sick leave days. Secondary outcomes are health-related quality of life, physical, affective and cognitive status, fatigue, costs of incapacity to work, treatment costs, out-of-pocket costs, self-efficacy, and patient satisfaction with therapy. Intervention effects are analyzed by a parallel-group comparison between the intervention and the control group. Furthermore, the long-term effects within the intervention group will be observed and a pre-post comparison of the control group, before and after receiving the intervention in MSnetWork, will be performed.
DISCUSSION
CONCLUSIONS
Due to the multiple approaches to patient-centered, multidisciplinary MS care, MSnetWork can be considered a complex intervention. The study design and linkage of comprehensive, patient-specific primary and secondary data in an outpatient setting enable the evaluation of this complex intervention, both on a qualitative and quantitative level. The basic assumption is a positive effect on the prevention or reduction of incapacity for work as well as on the patients' quality of life. If the project proves to be a success, MSnetWork could be adapted for the treatment of other chronic diseases with an impact on the ability to work and quality of life.
TRIAL REGISTRATION
BACKGROUND
The trial MSnetWork has been retrospectively registered in the German Clinical Trials Register (DRKS) since 08.07.2022 with the ID DRKS00025451 .
Identifiants
pubmed: 36494619
doi: 10.1186/s12883-022-02947-0
pii: 10.1186/s12883-022-02947-0
pmc: PMC9733358
doi:
Types de publication
Randomized Controlled Trial
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
472Subventions
Organisme : Innovation Fund (Germany, G-BA)
ID : 01NVF20025
Informations de copyright
© 2022. The Author(s).
Références
Mult Scler. 2009 Dec;15(12):1509-17
pubmed: 19995840
Gesundheitswesen. 2006 May;68(5):294-302
pubmed: 16773550
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
J Multidiscip Healthc. 2016 May 04;9:211-7
pubmed: 27217764
Psychother Psychosom Med Psychol. 1989 Jul;39(7):248-55
pubmed: 2762479
Br J Health Psychol. 2006 Sep;11(Pt 3):421-37
pubmed: 16870053
Mult Scler. 2002 Oct;8(5):359-65
pubmed: 12356200
Qual Life Res. 1995 Jun;4(3):187-206
pubmed: 7613530
Brain. 1999 May;122 ( Pt 5):871-82
pubmed: 10355672
Fortschr Neurol Psychiatr. 2020 Jul;88(7):436-450
pubmed: 32717768
BMC Med. 2010 Mar 24;8:18
pubmed: 20334633
Fortschr Neurol Psychiatr. 2022 Jan;90(1-02):42-48
pubmed: 34005824
Fortschr Neurol Psychiatr. 2013 Feb;81(2):95-103
pubmed: 23412961
Eval Program Plann. 1982;5(3):233-7
pubmed: 10259963
BMC Neurol. 2021 Dec 2;21(1):468
pubmed: 34856949
Qual Life Res. 2021 Mar;30(3):647-673
pubmed: 33284428
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957